Related Experiment Video
Updated: Jun 18, 2026
08:30
A Porcine Heterotopic Heart Transplantation Protocol for Delivery of Therapeutics to a Cardiac Allograft
Published on: February 14, 2022
Targeting heart failure therapeutics: a historical perspective
Guinevere A Murphy1, Mona Fiuzat, Michael R Bristow
1ARCA biopharma, Inc, 8001 Arista Place, Suite 200, Broomfield, CO 80021, USA.
Heart Failure Clinics
|December 1, 2009
Summary
Genetic variability impacts heart failure development and treatment, particularly neurohormonal systems like adrenergic receptors and the renin-angiotensin-aldosterone system. Future pharmacogenomic trials can improve patient outcomes.
Area of Science:
- Cardiovascular Genetics
- Pharmacogenomics
- Heart Failure Pathophysiology
Background:
- Genetic variability influences complex diseases, including heart failure.
- Neurohormonal systems play a critical role in cardiovascular regulation and disease.
- Understanding genetic contributions can personalize heart failure management.
Purpose of the Study:
- To review the role of genetic variability in heart failure.
- To explore genetic variations in key neurohormonal systems.
- To provide recommendations for future pharmacogenomic clinical trials.
Main Methods:
- Literature review of genetic variability in heart failure.
- Focus on adrenergic receptors, renin-angiotensin-aldosterone system, endothelin system, and natriuretic peptides.
- Examination of clinical trial design and regulatory considerations.
Main Results:
- Genetic variations in neurohormonal pathways are implicated in heart failure.
- Adrenergic receptors and the renin-angiotensin-aldosterone system are extensively studied.
- Pharmacogenomic approaches hold promise for targeted therapies.
Conclusions:
- Genetic variability is a key determinant in heart failure.
- Personalized treatment strategies based on genetic profiles are emerging.
- Optimizing clinical trial design is crucial for advancing pharmacogenomics in cardiology.
Related Concept Videos
01:30Heart Failure V: Medical Management
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
01:26Heart Failure Drugs: Inotropic Agents
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
01:22Heart Failure Drugs: β-Blockers
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
01:30Heart Failure IV: Classification and Diagnostic Evaluation
Heart failure can be classified in various ways, with the most common classifications based on physical activity limitations, disease progression, severity, and treatment strategies.The Functional Classification of Heart Failure divides patients into four categories based on physical activity limitation due to symptom burden.Class I: Patients in this class have cardiac disease but no physical activity limitations. Ordinary activities like walking, climbing stairs, or routine tasks do not cause...
01:22Heart Failure VI: Adjunct Therapies
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.